Botanix Pharmaceuticals (BOT) Q2 2024 TU earnings summary

Executive summary

• FDA approved Sofdra (sofpironium) topical gel, 12.45%, for primary axillary hyperhidrosis in adults and children 9+ years old, marking the first new chemical entity for this indication.

• Botanix plans a patient experience program in Q3 CY2024, with first Sofdra prescriptions expected in early Q4 CY2024 and a broader digital launch to follow.

• Institutional placement raised $70 million to fund Sofdra's US launch, including sales force, marketing, and manufacturing.

• Cash position at June 2024 quarter end was $79.31 million, with no debt.

Financial highlights

• Net operating cash outflows for the quarter were $2.63 million, mainly due to R&D, manufacturing, and corporate costs.

• Investing activities resulted in $0.55 million outflows, primarily for intellectual property.

• Financing activities provided $65.78 million net cash inflow, mainly from the $70 million placement.

• Cash and cash equivalents at quarter end totaled $79.31 million.

Outlook and guidance

• Sofdra's patient experience program launches in Q3 CY2024, with commercial sales and prescriptions expected in Q4 CY2024.

• Sales force deployment targeting high-prescribing dermatologists is planned for Q1 2025.